U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07736586) titled 'A Study of HL40626S Tablets in Healthy Adults' on July 24.
Brief Summary: This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.
Study Start Date: Aug. 16
Study Type: INTERVENTIONAL
Condition:
Psoriasis (PsO)
Skin Disease
Immune System Disease
Skin Diseases, Papulosquamous
Intervention:
DRUG: HL40626S tablets
25 and 100 mg tablets, anticipated dose range to be from 25 to 800 mg.
DRUG:...